Autres langues Wellbeing Digital Sciences Inc.

Actions

MEDI

CA94946J1084

Cours en clôture NEO Exchange Autres places de cotation 00:00:00 04/04/2023			Varia. 5j.	Varia. 1 janv.
0,015 ^CAD	+200,00%		-.--%	-.--%

2023	KGK Sciences Inc., filiale à part entière de Wellbeing Digital Sciences Inc. commence à recruter des participants dans le cadre d'un essai de psilocybine approuvé par Santé Canada, le premier du genre.	CI
2022	Wellbeing Digital Sciences Inc. nomme Mohammad Sharifi au conseil d'administration	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Wellbeing Digital Subsidiary KGK Science to Participate at the Mushroom Summit and Psychedelic Science Conference	19/06/23
Wellbeing Digital Enters into Share Purchase Agreement with Cardinal Group	16/06/23
Cardinal Group Companies LLC entered into an agreement to acquire KGK Science Inc. from Wellbeing Digital Sciences Inc. for $2 million.	16/06/23
Wellbeing Digital Subsidiary KGK Science to Participate at the Nutrition Industry Association Spring Conference	25/05/23
Wellbeing Subsidiary KGK Science Announces Successful Results of UP360, a Nutraceutical Ingredient Demonstrating Beneficial Immune Defense Response	03/05/23
Wellbeing Digital Sciences Inc.'s Wholly Owned Subsidiary KGK Sciences Inc Begins Recruitment in First-Of-Its-Kind Health Canada Approved Psilocybin Trial	18/04/23
Wellbeing Subsidiary KGK Science Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	18/04/23
Wellbeing Subsidiary KGK Science Receives Institutional Review Board Approval	11/04/23
Wellbeing Announces Cease Trade Order	06/04/23
IIROC Trading Halt - MEDI	06/04/23
Wellbeing Provides Bi-Weekly Default Status Report	16/03/23
Wellbeing Digital to Participate at the Benzinga Psychedelic Capital Conference	16/03/23
Wellbeing Digital to Participate at the Cantor Fitzgerald Virtual Panel Discussion	13/03/23
Wellbeing Digital to Participate in The Global Biomedical Design Conference	09/03/23
Wellbeing Subsidiary KGK Science Applies for a Controlled Substances Dealers License and Receives Approval to Proceed with Buildout	08/03/23
Wellbeing Provides Bi-Weekly Default Status Report	02/03/23
Wellbeing Digital to Participate in MarigoldLIVE: International Women’s Day Networking Event	01/03/23
Wellbeing Provides Bi-Weekly Default Status Report	16/02/23
Wellbeing Subsidiary KGK Science Announces Publication of Safety Studies on Paraxanthine and Comparison to Caffeine Toxicity.	15/02/23
Wellbeing Subsidiary KGK Science Receives Exemption Under Section 56 of the Controlled Drugs and Substances Act to Begin Psilocybin Clinical Trial	14/02/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Wellbeing Digital Sciences Inc.

Actions

MEDI

CA94946J1084

Autres langues

Filtres